← Back to screener

ACADIA PHARMACEUTICALS INC ACAD

Rank #2226 · Nasdaq · $3.5B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
28.4
P/E
-57.5
P/B
8.81
ROE
-15.3%
Op. Margin
-10.1%
Debt Ratio
114%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -57.5x, P/B 8.81x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -15.3%. Ranks in the top 78% of the universe.

Safety ★★★☆☆
Average

Debt ratio 114%. Ranks in the top 44% of the universe.

Growth ★★★★★
Excellent

Revenue growth of 40.4% year over year. Ranks in the top 9% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.0B$-0.0B$-0.0B$0.1B-710.516
2012$0.0B$0.0B$0.0B$0.0B35.872
2013$0.0B$-0.0B$-0.0B$0.0B-1105.620
2014$0.0B$-0.0B$-0.0B$0.0B-425.630
2015$0.0B$-0.0B$-0.0B$0.1B-3344.719
2016$0.0B$-0.1B$-0.1B$0.2B-77691.712
2017$0.0B$-0.2B$-0.2B$0.3B-269855.714
2018$0.1B$-0.3B$-0.3B$0.2B-218.425
2019$0.2B$-0.3B$-0.3B$0.5B-130.712
2020$0.3B$-0.2B$-0.2B$0.3B-73.025
2021$0.4B$-0.2B$-0.2B$0.5B-55.832
2022$0.5B$-0.3B$-0.3B$0.7B-59.223
2023$0.5B$-0.2B$-0.2B$0.6B-33.030
2024$0.5B$-0.2B$-0.2B$0.5B-43.259
2025$0.7B$-0.1B$-0.1B$0.4B-10.1114

← See the full screener